1
|
Landré T, Karaboué A, Buchwald ZS, Innominato PF, Qian DC, Assié JB, Chouaïd C, Lévi F, Duchemann B. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open 2024; 9:102220. [PMID: 38232612 PMCID: PMC10937202 DOI: 10.1016/j.esmoop.2023.102220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 12/09/2023] [Accepted: 12/15/2023] [Indexed: 01/19/2024] Open
Abstract
BACKGROUND Immune checkpoint inhibitors (ICIs) have become the standard of care for numerous malignancies. Emerging evidence suggests that the time of day (ToD) of ICI administration could impact the outcomes of patients with cancer. The consistency of ToD effects on ICI efficacy awaits initial evaluation. MATERIALS AND METHODS This meta-analysis integrates progression-free survival (PFS) and overall survival (OS) data from studies with a defined 'cut-off' ToD. Hazard ratios (HRs) [95% confidence interval (CI)] of an earlier progression or death according to 'early' or 'late' ToD of ICIs were collected from each report and pooled. RESULTS Thirteen studies involved 1663 patients (Eastern Cooperative Oncology Group performance status 0-1, 83%; males/females, 67%/33%) with non-small-cell lung cancer (47%), renal cell carcinoma (24%), melanoma (20%), urothelial cancer (5%), or esophageal carcinoma (4%). Most patients received anti-programmed cell death protein 1 or anti-programmed death-ligand 1 (98%), and a small proportion also received anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) (18%). ToD cut-offs were 13:00 or 14:00 (i.e. ICI median infusion time), for six studies, and 16:00 or 16:30 (i.e. reported threshold for weaker vaccination responses) for seven studies. Pooled analyses revealed that the early ToD groups had longer OS (HR 0.50, 95% CI 0.42-0.58; P < 0.00001) and PFS (HR 0.51, 95% CI 0.42-0.61; P < 0.00001) compared with the late ToD groups. CONCLUSIONS Patients with selected metastatic cancers seemed to largely benefit from early ToD ICI infusions, which is consistent with circadian mechanisms in immune-cell functions and trafficking. Prospective randomized trials are needed to establish recommendations for optimal circadian timing of ICI-based cancer therapies.
Collapse
Affiliation(s)
- T Landré
- Hôpitaux Universitaires Paris Saint-Denis, UCOG, Assistance Publique - Hôpitaux de Paris, Sevran
| | - A Karaboué
- Medical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil; UPR 'Chronotherapy, Cancer and Transplantation', Paris-Saclay University Medical School, Villejuif, France
| | - Z S Buchwald
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA
| | - P F Innominato
- Oncology Department, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor; Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK
| | - D C Qian
- Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA
| | - J B Assié
- Pneumology Service, CHI Créteil, Créteil; Inserm U955, UPEC, IMRB, Créteil
| | - C Chouaïd
- Pneumology Service, CHI Créteil, Créteil; Inserm U955, UPEC, IMRB, Créteil
| | - F Lévi
- UPR 'Chronotherapy, Cancer and Transplantation', Paris-Saclay University Medical School, Villejuif, France; Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK; Gastro-intestinal and Medical Oncology Service, Paul-Brousse Hospital, Assistance Publique - Hôpitaux de Paris, Villejuif
| | - B Duchemann
- Thoracic and Medical Oncology Unit, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris, Bobigny, France.
| |
Collapse
|
2
|
Zhang Y, Giacchetti S, Parouchev A, Hadadi E, Li X, Dallmann R, Xandri-Monje H, Portier L, Adam R, Lévi F, Dulong S, Chang Y. Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock. Cell Cycle 2018; 17:33-42. [PMID: 29099263 PMCID: PMC5815427 DOI: 10.1080/15384101.2017.1387695] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 09/27/2017] [Accepted: 09/29/2017] [Indexed: 12/31/2022] Open
Abstract
Everolimus (EV), a rapamycin analogue mTOR inhibitor, is used in the clinic to treat Estrogen positive (ER+) breast cancer in order to avoid the resistance to hormonotherapy. Here, we investigated whether EV efficacy varied according to administration timing by using the ER+ breast cancer cell line MCF-7 as model system. Our results showed that instead of apoptosis, EV induced a G0/G1 phase blockage of MCF-7 cells. Following serum shock, MCF-7 cells displayed a statistically significant 24h rhythm of mammalian target of Rapamycin (mTOR) activity, but perturbed circadian clock genes oscillations. Interestingly, the different delivery schedule of EV presented different efficacy in G0/G1 phase blockage in serum shocked MCF-7 cells. Moreover, serum shock induced also a circadian-like oscillation in expression or activity of several important G1 phase progression proteins, such as Cyclin D1 and phosphorylated Retinoblastoma protein (RB). Inhibition mTOR activity by EV reduced Cyclin D1 and Cyclin D3 protein level as well as RB phosphorylation level. Taken together, the results indicated that serum shock synchronization induced a circadian oscillation in mTOR activity in MCF-7 cells, which rhythmically regulated the synthesis or phosphorylation of key G1 progression proteins, such as Cyclin D1 and phosphorylated RB, ultimately resulting in different G0/G1 blockage efficiency according to different EV administration timing.
Collapse
Affiliation(s)
- Yuan Zhang
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
| | - Sylvie Giacchetti
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Centre des Maladies du Sein, Hôpital Saint-Louis AP-HP, Paris, France
| | | | - Eva Hadadi
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
| | - Xiaomei Li
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
| | - Robert Dallmann
- Division of Biomedical Sciences and Zeeman Institute: SBIDER, Warwick Medical School, University of Warwick, CV4 7AL Coventry, UK
| | - Helena Xandri-Monje
- Division of Biomedical Sciences and Zeeman Institute: SBIDER, Warwick Medical School, University of Warwick, CV4 7AL Coventry, UK
| | - Lucie Portier
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
| | - René Adam
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
- Hôpital Paul Brousse AP-HP, Villejuif, Val-de-Marne, France
| | - Françis Lévi
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
- Hôpital Paul Brousse AP-HP, Villejuif, Val-de-Marne, France
- Division of Biomedical Sciences and Zeeman Institute: SBIDER, Warwick Medical School, University of Warwick, CV4 7AL Coventry, UK
| | - Sandrine Dulong
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
| | - Yunhua Chang
- INSERM, UMR935 Modèles de cellules souches malignes et thérapeutiques, Villejuif, Val-de-Marne, France
- Université Paris-Sud, Orsay, Essonne, France
| |
Collapse
|
3
|
Komarzynski S, Lévi F, Ballesta A, Bouchahda M, Haydar M, Ulusakarya A, Morère J, Innominato PF. 1038 OBJECTIVE CORRELATES OF SLEEP COMPLAINT IN CANCER PATIENTS ON CHEMOTHERAPY TELE-MONITORED AT HOME: NIGHT-BY-NIGHT ANALYSIS. Sleep 2017. [DOI: 10.1093/sleepj/zsx050.1037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
4
|
Affiliation(s)
- F. Lévi
- Laboratoire “Rythmes Biologiques et Chronothérapeutique,” I.C.I.G., Hôpital Paul Brousse, Villejuif, France
| | - G. Metzger
- Laboratoire “Rythmes Biologiques et Chronothérapeutique,” I.C.I.G., Hôpital Paul Brousse, Villejuif, France
| | - P. Deprés-Brummer
- Laboratoire “Rythmes Biologiques et Chronothérapeutique,” I.C.I.G., Hôpital Paul Brousse, Villejuif, France
| |
Collapse
|
5
|
Abstract
The circadian timing system determines the optimal timing and waveform of drug tolerability, yet treatment itself can alter this system. Gemcitabine is an antimetabolite agent that is active against lung and pancreatic cancers. Tolerability for this drug is best following dosing at ZT 11 in mice. The authors investigated the effects of gemcitabine on the circadian rhythms in body temperature and rest activity as physiological markers of the circadian timing system. Healthy unrestrained B6D2F1 mice implanted with radiotelemetry transmitters were kept in LD 12:12 prior to receiving a single intravenous dose of gemcitabine (200, 400, or 600 mg/kg) at ZT 11 or 23. Gemcitabine (400 mg/kg) transiently suppressed the body temperature rhythm in 50% of the mice dosed at ZT 23, as compared to none of the mice treated at ZT 11 within the 2 days following drug dosing (Fisher 's exact test p = 0.04). The rest-activity circadian rhythm was suppressed in 40% (ZT 11) and 50% (ZT 23) of the mice, respectively. In the mice with persistent circadian rhythms, gemcitabine delivery at ZT 23 resulted in more prominent decreases and slower recovery of circadian mesor and amplitude of both rhythms as compared to mice treated at ZT 11. Gemcitabine also induced a transient internal desynchronization between temperature and activity rhythms following dosing at ZT 23 but not at ZT 11. The delivery of a single therapeutic dose of gemcitabine near its time of least toxicity produced least alterations in circadian physiological outputs, a finding that suggests that the extent of circadian disruption contributes to toxicokinetic processes.
Collapse
Affiliation(s)
- X M Li
- INSERM, U776 "Rythmes biologiques et cancers", Univ Paris-Sud, Hôpital Paul Brousse, 94800 Villejuif, France.
| | | |
Collapse
|
6
|
Giacchetti S, Dugué PA, Innominato PF, Bjarnason GA, Focan C, Garufi C, Tumolo S, Coudert B, Iacobelli S, Smaaland R, Tampellini M, Adam R, Moreau T, Lévi F. Sex moderates circadian chemotherapy effects on survival of patients with metastatic colorectal cancer: a meta-analysis. Ann Oncol 2012; 23:3110-3116. [PMID: 22745214 DOI: 10.1093/annonc/mds148] [Citation(s) in RCA: 90] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Molecular circadian clocks can modify cancer chemotherapy effects, with a possible moderation according to sex differences. We investigated whether sex determine the optimal delivery schedule of chemotherapy for metastatic colorectal cancer. PATIENTS AND METHODS A meta-analysis was performed using individual data from three international Phase III trials comparing 5-fluorouracil, leucovorin and oxaliplatin administered in chronomodulated (chronoFLO) or conventional (CONV) infusions. The data from 345 females and 497 males were updated at 9 years. The main end point was survival. RESULTS Overall survival was improved in males on chronoFLO when compared with CONV (P = 0.009), with respective median values of 20.8 (95% CL, 18.7 to 22.9) and 17.5 months (16.1 to 18.8). Conversely, median survival was 16.6 months (13.9 to 19.3) on chronoFLO and 18.4 months (16.6 to 20.2) on CONV in females (P = 0.012). The sex versus schedule interaction was a strong predictive factor of optimal treatment schedule, with a hazard ratio of 1.59 (1.30 to 1.75) for overall survival (P = 0.002) in multivariate analysis. CONCLUSIONS Males lived significantly longer on chronomodulated chemotherapy rather than on conventional chemotherapy. The current chronoFLO schedule deserves prospective assessment as a safe and more effective first-line treatment option than conventional delivery for male patients.
Collapse
Affiliation(s)
- S Giacchetti
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France
| | - P A Dugué
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France
| | - P F Innominato
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France
| | - G A Bjarnason
- Division of Medical Oncology, Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, Canada
| | - C Focan
- Department of Medical Oncology, Centre Hospitalier Chrétien, Clinique Saint-Joseph, Liège, Belgium
| | - C Garufi
- Department of Medical Oncology C, Istituto Regina Elena, Roma
| | - S Tumolo
- Department of Medical Oncology, Azienda Ospedaliera Santa Maria Degli Angeli, Pordenone, Italy
| | - B Coudert
- Department of Medical Oncology, Georges-François Leclerc Center, Dijon, France
| | - S Iacobelli
- Department of Medical Oncology, G. D'Annunzio di Chieti University, Chieti, Italy
| | - R Smaaland
- Department of Hematology and Oncology, Stavanger University Hospital, Stavanger; University of Bergen, Norway
| | - M Tampellini
- Department of Medical and Biological Sciences, University of Torino, San Luigi Gonzaga Hospital, Orbassano, Torino, Italy
| | - R Adam
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France; Onco-surgery Unit, Hepato-biliary Center, France
| | - T Moreau
- Department of Biostatistics, INSERM U1018, Paul Brousse Hospital, Villejuif, France
| | - F Lévi
- INSERM, UMRS776 'Biological Rhythms and Cancers', Villejuif; Paris South University, UMR-S0776, Orsay; APHP, Chronotherapy Unit, Department of Oncology, Paul Brousse hospital, Villejuif; Faculty of Medicine, Paris XI University, le Kremlin-Bicêtre, France.
| |
Collapse
|
7
|
Wicherts DA, de Haas RJ, Sebagh M, Saenz Corrales E, Gorden DL, Lévi F, Paule B, Azoulay D, Castaing D, Adam R. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases. Br J Surg 2010; 98:399-407. [PMID: 21254017 DOI: 10.1002/bjs.7368] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/26/2010] [Indexed: 12/11/2022]
Abstract
BACKGROUND The impact of bevacizumab on functional recovery and histology of the liver was evaluated in patients undergoing hepatic resection for colorectal liver metastases (CLM) following bevacizumab treatment. METHODS Consecutive patients who had resection of CLM between July 2005 and July 2009 following preoperative chemotherapy were identified retrospectively from a prospectively collected database. Patients who had received bevacizumab before the last chemotherapy line were excluded. Postoperative liver function and histology were compared between patients with and without bevacizumab treatment. Recorded parameters included serum prothrombin time, total bilirubin concentration, and levels of aspartate and alanine aminotransferase and γ-glutamyltransferase. RESULTS Of 208 patients identified, 67 had received last-line bevacizumab, 44 were excluded and 97 had not received bevacizumab. Most patients in the bevacizumab group (66 per cent) received a single line of chemotherapy. Bevacizumab was most often combined with 5-flurouracil/leucovorin and irinotecan (68 per cent). The median number of bevacizumab cycles was 8·6 (range 1-34). Bevacizumab administration was stopped a median of 8 (range 3-19) weeks before surgery. There were no deaths. Postoperative morbidity occurred in 43 and 36 per cent of patients in the bevacizumab and no-bevacizumab groups respectively (P = 0·353). The mean(s.d.) degree of tumour necrosis was significantly higher in the bevacizumab group (55(27) versus 32(29) per cent; P = 0·001). Complete pathological response rates were comparable (3 versus 8 per cent; P = 0·307). Postoperative changes in functional parameters and objective signs of hepatic toxicity were similar in both groups. CONCLUSION Preoperative administration of bevacizumab does not seem to affect functional recovery of the liver after resection of CLM. Tumour necrosis is increased following bevacizumab treatment.
Collapse
Affiliation(s)
- D A Wicherts
- Centre Hépato-Biliaire, Assistance Publique-Hôpitaux de Paris Hôpital Paul Brousse, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Bouchahda M, Macarulla T, Liedo G, Lévi F, Elez ME, Paule B, Karaboué A, Artru P, Tabernero J, Machover D, Innominato P, Goldschmidt E, Bonnet D, Ducreux M, Castagne V, Guimbaud R. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med Oncol 2010; 28 Suppl 1:S253-8. [PMID: 21053102 DOI: 10.1007/s12032-010-9716-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2009] [Accepted: 10/05/2010] [Indexed: 11/30/2022]
Abstract
Cetuximab was approved using a weekly schedule, alone or in combination with chemotherapy (CT). However, many CT regimens in metastatic colorectal cancer (CRC) are delivered every 2 weeks (q2wks). Preliminary data suggested that a simplified schedule using cetuximab q2wks, 500 mg/m² would be equivalent to the standard weekly administration. Medical data of all patients with advanced CRC who received cetuximab q2wks were retrospectively collected and checked for consistency by an independent monitor in 4 European centers. Ninety-one patients were treated between 2005 and 2007 when the K-RAS mutational status of tumors was not determined routinely. They received a median of 4 (0-5) previous drugs, including previous weekly cetuximab in 38.5% of patients. Cetuximab q2wks was associated with an irinotecan-based regimen in 85.7% of patients. The median number of cetuximab administrations was 6 (1-23). Skin toxicity was observed in 68.2% of evaluable patients (grade 3 in 15%). Only one grade 1 allergy was reported. In the 84 patients beyond first-line therapy, response rate was 29.3%. The median progression-free survival was 3.0 months (range 2.2-3.8), and median overall survival was 9.0 months (range 6.2-11.8). Cetuximab q2wks appears safe and effective in heavily pretreated patients and convenient in combination with q2wks CT schedules.
Collapse
Affiliation(s)
- M Bouchahda
- Service d'Oncologie Médicale, Oncology Unit, Hopital Paul Brousse, 12 avenue Paul Vaillant Couturier, 94800 Villejuif, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
9
|
Ahowesso C, Piccolo E, Li XM, Dulong S, Hossard V, La Sorda R, Filipski E, Tinari N, Delaunay F, Iacobelli S, Lévi F. Relations between strain and gender dependencies of irinotecan toxicity and UGT1A1, CES2 and TOP1 expressions in mice. Toxicol Lett 2009; 192:395-401. [PMID: 19931604 DOI: 10.1016/j.toxlet.2009.11.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2009] [Revised: 10/31/2009] [Accepted: 11/15/2009] [Indexed: 10/20/2022]
Abstract
Irinotecan hydrochloride (CPT-11) can display severe toxicities in individual cancer patients. CPT-11 is bio-activated through CES, detoxified through UGT1A1 and inhibits TOP1. CPT-11 toxicity and UGT1A1, CES2 and TOP1 mRNAs and UGT1A1 protein were determined in male and female C57BL/6, B6D2F1 and B6CBAF1, as potential models for tailoring CPT-11 delivery. CPT-11 was administered intravenously (40-90 mg/kg/day for 4 days at 7h after light onset). The relations between dose and lethal toxicity or body weight loss were steep and similar in C57BL/6 (lethality, p=0.001; weight loss, p=0.002) and B6D2F1 (p=0.01; p=0.03, respectively), but weak in B6CBAF1. Females displayed less toxicity than males (p<0.001). Mean mRNA expression of UGT1A1 was highest in B6CBAF1 (p=0.039) and in females (p<0.001). Both CES2 and TOP1 varied according to strain and gender (p<0.001). The three gene expression data explained the most severe toxicity of CPT-11 in male B6D2F1, but displayed inconsistent relations with toxicity in the other groups. Mean UGT1A1 protein expression was highest in males as compared to females, and so by approximately 8-fold in C57BL/6 as compared to B6D2F1 (p<0.0001). Genetic background and gender significantly altered the molecular prediction of irinotecan toxicity by UGT1A1, CES2 and TOP1 mRNA expressions.
Collapse
Affiliation(s)
- C Ahowesso
- INSERM, U776 Rythmes Biologiques et Cancers, Hôpital Paul Brousse, Villejuif, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, Azoulay D, Bismuth H, Castaing D, Adam R. Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4097] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4097 Background: Regenerative nodular hyperplasia (RNH) represents the worst evolutive stage of vascular lesions induced by prolonged chemotherapy on the liver. Its incidence and impact on the outcome of resection for colorectal liver metastases (CLM) are however unknown. We evaluated the effect of RNH on postoperative morbidity and assessed its evolution in time at repeat hepatectomy. Methods: All patients that underwent hepatectomy for CLM between January 1990 and November 2006 after 1 line of chemotherapy of more than 6 cycles were included. Detailed histopathologic analysis of the nontumoral liver was performed at first and repeat hepatectomies according to a standard format. Results: Of 146 included patients, 24 (16%) received 5- fluorouracil (5-FU) and leucovorin (LV) alone, 92 (63%) had 5-FU, LV and oxaliplatin, 18 (12%) had 5-FU, LV and irinotecan, and 12 (8%) were treated by 5-FU, LV, oxaliplatin and irinotecan. Overall, RNH occurred in 22 of 146 patients (15%). Patients treated by oxaliplatin more often had RNH compared to oxaliplatin-naïve patients (22% vs 4%) (P=0.003). The presence of RNH was associated with increased postoperative hepatic morbidity (23% vs 11%) (P=0.05). None of the RNH patients died within 60 days postoperatively. A preoperative gamma-glutamyltransferase level >80 U/L and a total bilirubin level >15 μmol/L were independent predictive factors of RNH at first hepatectomy. Two of 22 patients with RNH underwent repeat hepatectomy. RNH disappeared at second hepatectomy in both patients following prolonged treatment with irinotecan. Conclusions: Patients with CLM that receive prolonged courses of preoperative oxaliplatin have an increased risk of RNH and associated postoperative hepatic morbidity. Upfront treatment with short courses of highly effective regimens may therefore be most appropriate. In addition, the continuation of oxaliplatin should be discouraged in case of RNH to avoid its negative effects on further surgery. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | | | - M. Sebagh
- Hôpital Paul Brousse, Villejuif, France
| | - O. Ciacio
- Hôpital Paul Brousse, Villejuif, France
| | - F. Lévi
- Hôpital Paul Brousse, Villejuif, France
| | - B. Paule
- Hôpital Paul Brousse, Villejuif, France
| | | | | | | | - R. Adam
- Hôpital Paul Brousse, Villejuif, France
| |
Collapse
|
11
|
Adam R, Wicherts DA, de Haas RJ, Lévi F, Paule B, Azoulay D, Castaing D. Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.4093] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4093 Background: The influence of bevacizumab on postoperative morbidity in patients with colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated. However, in spite of a potential inhibition of liver regeneration, its impact on postoperative liver function recovery remains unknown. Methods: From July 2005 to December 2007, we evaluated 37 patients treated with bevacizumab prior to hepatectomy. Postoperative evolution of liver function variables was compared with that of 70 bevacizumab-naïve patients. Recorded parameters included prothrombin time, serum aspartate and alanine aminotransferase levels, and serum gamma-glutamyltransferase and total bilirubin levels. Results: Most patients of the bevacizumab group received 1 line of chemotherapy (62% vs 54% in the control group) (P=0.43). Bevacizumab was combined to 5-fluorouracil (5-FU), leucovorin (LV) and irinotecan or 5-FU, LV and oxaliplatin in the last preoperative line, in 57% and 30% of cases, respectively. Patients received a mean total number of 10.4+5.7 and 11.1+6.2 cycles of preoperative chemotherapy in the bevacizumab and control group (P=0.56). The median number of administered bevacizumab cycles was 6 (range: 3–25). Bevacizumab administration was stopped at a median of 7.9 weeks before surgery (range: 3.6–18.0). Major hepatectomies were performed in 41% and 36% of bevacizumab and control patients, respectively (P=0.62). Baseline liver function tests as well as postoperative liver function recovery were similar between patients treated with or without bevacizumab (Table). Postoperative morbidity occurred in 35% of bevacizumab patients and in 43% of control patients (P=0.44). Conclusions: Preoperative bevacizumab treatment has no impact on short-term liver function recovery after hepatic resection for CLM and has no deleterious effect on the incidence of postoperative morbidity. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- R. Adam
- Hôpital Paul Brousse, Villejuif, France
| | | | | | - F. Lévi
- Hôpital Paul Brousse, Villejuif, France
| | - B. Paule
- Hôpital Paul Brousse, Villejuif, France
| | | | | |
Collapse
|
12
|
Deprés‐Brummer P, Metzger G, Larue‐Achagiotis C, Touitou Y, Lévi F. Prolonged exposure of rats to constant light: An animal model of environmentally induced functional suppression of the circadian system. BIOL RHYTHM RES 2008. [DOI: 10.1080/09291019409360293] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- P. Deprés‐Brummer
- a ICIG, Hôpital Paul Brousse , Lab. “Rythmes Biologiques et Chronothérapeutique” , Villejuif
| | - G. Metzger
- a ICIG, Hôpital Paul Brousse , Lab. “Rythmes Biologiques et Chronothérapeutique” , Villejuif
| | | | - Y. Touitou
- c Faculté de Médecine Pitié‐Salpétrière , Lab. de Biochimie Médicale , Paris, F‐75013, France
| | - F. Lévi
- a ICIG, Hôpital Paul Brousse , Lab. “Rythmes Biologiques et Chronothérapeutique” , Villejuif
| |
Collapse
|
13
|
Lévi F. Le système circadien : déterminant et cible de l’activité des traitements anticancéreux. Annales Pharmaceutiques Françaises 2008; 66:175-84. [DOI: 10.1016/j.pharma.2008.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/15/2008] [Indexed: 10/21/2022]
|
14
|
Bouchahda M, Macarulla T, LIedo G, Lévi F, Elez ME, Karaboué A, Artru P, Tabernero J, Castagne V, Gimbaud R. Efficacy and safety of cetuximab (C) given with a simplified, every other week (q2w), schedule in patients (pts) with advanced colorectal cancer (aCRC): A multicenter, retrospective study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Iacobelli S, Innominato P, Piantelli M, Bjarnason GA, Coudert B, Focan C, Giacchetti S, Poncet A, Garufi C, Lévi F. Tumor clock protein PER2 as a determinant of survival in patients (pts) receiving oxaliplatin-5-FU-leucovorin as first-line chemotherapy for metastatic colorectal cancer (MCC). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.11032] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Castagné V, Goldschmidt E, Lévi F, Brahimi N, Almohamad W, Machover D, Karaboué A, Habert H, Bonhomme-Faivre L, Bouchahda M. Medico-pharmaceutical approach to reduce costs of infusion-related reactions (IRR) associated with cetuximab at Paul Brousse hospital. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Lévi F, Parganiha A, Innominato P, Karaboué A, Poncet A, Moreau T, Garufi C, Focan C, Coudert B, Bjarnason GA. Relevance of circadian coordination for the outcome of patients with advanced gastro-intestinal (GI) cancer. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.15043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Adam R, Wicherts DA, de Haas RJ, Ciacio O, Lévi F, Paule B, Ducreux M, Azoulay D, Castaing D. Patients with initially irresectable colorectal liver metastases: Is there a possibility of cure by an oncosurgical approach? J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4023] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
de Haas RJ, Wicherts DA, Flores E, Ducreux M, Lévi F, Paule B, Azoulay D, Castaing D, Lemoine A, Adam R. Tumor marker kinetics: Better than imaging to assess response to chemotherapy? J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.4072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Garufi C, Focan C, Tumolo S, Coudert B, Iacobelli S, Tubiana N, Marreaud S, Lentz M, Gorlia T, Lévi F. Time finding study of chronomodulated irinotecan (I), fluorouracil (F), leucovorin (L) and oxaliplatin (O) (chronoIFLO) against metastatic colorectal cancer: Results from randomized EORTC 05011 trial. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2566] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2566 Background: We previously showed that a) irinotecan (I) could be combined with chronoFLO in MMC patients; b) least toxic times (LTT) for combined I and oxaliplatin respectively correspond to the middle of the rest-phase and the middle of acivity-phase in tumor-bearing mice; c) chrono I showed adequate activity in a randomized phase II trial; and d) MMC resistance can be partly overcome with chronoIFL. Methods: The objective was to identify the LTT for I characterized by a minimal dose reduction/delay among the first 3 courses (c). Assuming that the toxic effect of I had a 24-h periodicity patients were randomized in 6 groups with I peak delivery (180 mg/m2, 6-h sinusoidal infusion on day 1) at 1:00, 5:00, 9:00 am, 1:00, 5:00, or 9:00 pm. . All the groups received also chronoFLO on days 2–5, q 3 weeks (F 700 mg/m2/d & L 150 mg/m2/d; from 22:15 to 9:45 with peak delivery at 4:00 , O 20 mg/m2/d from 10:15 to 21:45, with peak delivery at 16:00). Based on a logistic regression model, a 15% reduction in toxic events in the first 3 c, 186 patients were considered necessary to estimate the LTT with a 95% CI (calculated by bootsrap) of less than 6 h. Results: 197 of 199 randomized MMC patients were considered for tolerability and safety with median age 61 years (30–81), sex (M 68% - F 32%) and PS (0/1/2 73/23/4%); therapy was 1st line in 77 patients and 2nd line in 23%. Thithy-one percent of severe protocol violations occurred, 16% of pump malfunctions (>10% dose delivery deviation). Median number of c was 6 (1–18). There were 3 toxic deaths. The observed LTT for I tolerability was 3:15 am (95 CI: 3:40–1:50 pm, NS). Grade 3–4 diarrhea ranged from 34 to 51.6% with LTT at 1:53 pm (4:29 -2:53 am, not significant, NS); neutropenia from 9 to 25% with LTT at 3:26 pm (10:50 - 4:55 am, NS). Age was a negative prognostic factor for diarrhea (p =0.01). Conclusion: This trial failed to show a statistically significant LTT for this combination in MCC patients. The safety profile of I combined with ChronoIFLO was acceptable, with diarrhea and neutropenia within previously reported range. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- C. Garufi
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - C. Focan
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - S. Tumolo
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - B. Coudert
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - S. Iacobelli
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - N. Tubiana
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - S. Marreaud
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - M. Lentz
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - T. Gorlia
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| | - F. Lévi
- Istituto Regina Elena, Rome, Italy; Clinique Saint Joseph, Liege, Belgium; Ospedale S. Maria degli Angeli, Pordenone, Italy; Centre Georges-Francois Leclerc, Dijon, France; Università G. D’Annunzio, Chieti, Italy; CHRU de Limoges, Limoges, France; EORTC, Brussels, Belgium; Hopital Paul Brousse, Villejuif, France
| |
Collapse
|
21
|
Li XM, Claustrat B, Hastings MH, Albrecht U, Lévi F. [Interactions between clock gene mutation, circadian phenotype and tumor growth in mice]. ACTA ACUST UNITED AC 2007; 55:194-7. [PMID: 17412525 DOI: 10.1016/j.patbio.2006.12.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2006] [Accepted: 11/02/2006] [Indexed: 10/23/2022]
Abstract
The relation between circadian physiology (rest-activity and body temperature) and the growth of a grafted tumor (Glasgow osteosarcoma-GOS) was investigated in the mice with mutation of clock gene (ClockDelta19(-)) or gene controlled by the clock (Vpac(-/-)). Circadian rhythms in temperature and activity were stable, with an approximately 24-h period in all the mice synchronized by the alternation of 12 h of light and 12 h of darkness (LD 12:12). Following exposure to constant darkness (DD), both rhythms persisted in ClockDelta19(-), yet with a lengthening of the period by 4.5 h compared to wild type. In DD, the amplitude increased by 45.9% for the temperature rhythm (p<0.001) and by 17.4% for the activity one (p=0.08) as compared to LD 12:12 in ClockDelta19(-). The improvement of circadian coordination and/or the lengthening of the circadian period observed in ClockDelta19(-) kept in DD was associated with a moderate slowing down of tumor growth. Although the exposure to DD ablated the activity and temperature rhythms in Vpac(-/-), no modification in tumor growth was observed as compared to wide type or Vpac(-/-) in LD 12:12. Major alternations of circadian physiology can result from interactions between photoperiodic environment and mutation of clock gene or gene controlled by the clock. In these conditions, we have shown that the alternation of the circadian phenotype does not seem to constitute an essential determinant of the growth of a grafted tumor.
Collapse
Affiliation(s)
- X-M Li
- Inserm, U 776 chronothérapeutique des cancers, 94800 Villejuif, France.
| | | | | | | | | |
Collapse
|
22
|
Beau J, Iurisci I, Beau T, Lévi F. [Dynamic circadian system patients under chimiotherapy]. Pathol Biol (Paris) 2007; 55:171-5. [PMID: 17412521 DOI: 10.1016/j.patbio.2006.12.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2006] [Accepted: 11/02/2006] [Indexed: 05/14/2023]
Abstract
Currently, the circadian timing system of cancer patients can be estimated with wrist actimetry, which provides numerical data on the continuous activity of patients. The method of processing of these data, which we implemented, aims at answering the following questions: is the circadian timing system stable before chemotherapy, is this system extensively modified by chemotherapy, are there structural modifications or a decrease in activity amplitude produced by chemotherapy and how does the circadian activity rhythm recover? Here, we determine a circadian model function using a wavelet transform prior to chemotherapy delivery. Then we measure the correlation between this model function and the evolution of the circadian rhythm of activity over the whole observation span during and after chemotherapy. The application of this method to the record of activity rhythms in cancer patients highlights the characteristics and the recovery pattern of chemotherapy-induced alterations of the circadian timing system.
Collapse
Affiliation(s)
- J Beau
- Rythmes biologiques et cancers, Inserm U 776, hôpital Paul-Brousse, 12, avenue P.-Vaillant-Couturier, 94800 Villejuif, France.
| | | | | | | |
Collapse
|
23
|
Focan C, Lévi F, Innominato P. [Circadian behaviour of host versus tumour outcome. A review]. Pathol Biol (Paris) 2007; 55:178-80. [PMID: 17412524 DOI: 10.1016/j.patbio.2006.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2006] [Accepted: 11/02/2006] [Indexed: 05/14/2023]
Abstract
The authors reviewed experimental and clinical data emphasizing the importance for host to keep a reference circadian rythmicity. This assessment seems true both in the cancerogenesis phase, as well in the active phase of tumoural disease.
Collapse
Affiliation(s)
- C Focan
- Département de médecine interne, oncologie, CHC - Clinique Saint-Joseph, rue de Hesbaye 75, 4000 Liège, Belgique.
| | | | | |
Collapse
|
24
|
Teboul M, Barrat-Petit MA, Li XM, Claustrat B, Formento JL, Milano G, Lévi F, Delaunay F. [Circadian clock gene expression in human peripheral blood mononuclear cells]. Pathol Biol (Paris) 2007; 55:208-10. [PMID: 17412523 DOI: 10.1016/j.patbio.2006.12.026] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2006] [Accepted: 11/02/2006] [Indexed: 11/17/2022]
Abstract
Circadian clock genes have been identified in humans but information regarding their expression has remained very limited. However from a basic point as well as in a diagnostic and therapeutic perspective, it is important to evaluate molecular clock gene expression. Peripheral blood mononuclear cells represent an ideal material to investigate non-invasively the human clock at the molecular level. Several studies including ours reported rhythmic expression of clock genes in these cells, with significant intersubject variability of expression. In addition, our results reveal the existence of different chronotypes of clock gene expression patterns and suggest specific regulatory mechanisms in these human cells as compared to other peripheral tissues.
Collapse
Affiliation(s)
- M Teboul
- Université de Nice - Sophia-Antipolis, CNRS UMR 6548, parc Valrose, 06108 Nice, France.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Lévi F, Filipski E, Iurisci I, Li XM, Innominato P. Cross-talks between circadian timing system and cell division cycle determine cancer biology and therapeutics. Cold Spring Harb Symp Quant Biol 2007; 72:465-75. [PMID: 18419306 DOI: 10.1101/sqb.2007.72.030] [Citation(s) in RCA: 62] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/13/2023]
Abstract
The circadian clock orchestrates cellular functions over 24 hours, including cell divisions, a process that results from the cell cycle. The circadian clock and cell cycle interact at the level of genes, proteins, and biochemical signals. The disruption or the reinforcement of the host circadian timing system, respectively, accelerates or slows down cancer growth through modifications of host and tumor circadian clocks. Thus, cancer cells not only display mutations of cell cycle genes but also exhibit severe defects in clock gene expression levels or 24-hour patterns, which can in turn favor abnormal proliferation. Most of the experimental research actively ongoing in this field has been driven by the original demonstration that cancer patients with poor circadian rhythms had poor quality of life and poor survival outcome independently of known prognostic factors. Further basic research on the gender dependencies in circadian properties is now warranted, because a large clinical trial has revealed that gender can largely affect the survival outcome of cancer patients on chronotherapeutic delivery. Mathematical models further show that the therapeutic index of chemotherapeutic drugs can be optimized through distinct delivery profiles, depending on the initial host/tumor status and variability in circadian entrainment and/or cell cycle length. Clinical trials and systems-biology approaches in cancer chronotherapeutics raise novel issues to be addressed experimentally in the field of biological clocks. The challenge ahead is to therapeutically harness the circadian timing system to concurrently improve quality of life and down-regulate malignant growth.
Collapse
Affiliation(s)
- F Lévi
- INSERM, U776 Rythmes biologiques et cancers, Hôpital Paul Brousse, Villejuif, F-94807, France
| | | | | | | | | |
Collapse
|
26
|
Coudert B, Focan C, Genet D, Giacchetti S, Lentz M, Marreaud S, Baron B, Gorlia T, Lévi F. Optimal circadian time of vinorelbine (V) combined with chronomodulated 5-FU in pretreated metastatic breast cancer patients. EORTC 05971 randomized multicenter study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2066] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2066 Background: Chronotherapy is an aim to increase efficacy/toxicity ratio. Objectives: to define the dosing least toxic time (DLTT) of V (30 mg/m2/d at D1 and D6), combined with chrono 5-FU (10 pm-10 am) (850 mg/m2 D2-D5) over 3 courses q3w. Methods: A logistic regression model (LRM) estimated the DLTT assuming a sinusoidal distribution over time (i.e. over the 8 different arms) of the toxicity rate observed in each arm. The associated 90% confidence limits (CL) has been obtained by bootstrap method. Results: 90 patients were recruited. Toxicity in 46 pts led to the V dosage reduction to 25 mg/m2/d. 40 and 43 pts were assigned the V30 and the V25 regimen. 12% pts went off for toxicity, 5% for PD, 1% for refusal, 1% for unrelated death. 224 cycles were analyzed . V and 5FU relative dose intensities were 79.4% and 78.2% in the V30 while 88.1% and 87.4% in the V25 pts. Over the 3 cycles, toxicity by cycle was: Grade (G) 3 and G4 leucopenia in 47% and 29%, G3 and G4 neutropenia in 12% and 77%. G3 febrile neutropenia in 34%. G2 thrombopenia and anemia in 4% each. Other G3 and G 4 toxicity were stomatitis (12%), alopecia (7%), and less than 5%: cardiovascular, lethargy, diarrhea, constipation, other gastrointestinal, infection, sensory, pulmonary. LRM could not demonstrate a DLTT for the neutropenia G3–4 incidence, the primary endpoint. However, based on the stratified by dose analysis, a 90% CI of less than 6 hours width was observed: - around 17H17 [14H04–20H03] for the incidence of leucopenia G3–4. - around 8H16 [06H04–10H39] for tolerability (dose reduction, dose delay or treatment interruption for toxicity reason). This suggests that treatment tolerability was influenced by other factors beside leucopenia nadir. No other 90% CI of less than 6 hours width could be observed for other toxicity endpoints. Conclusions: Using a novel time finding study design with ad hoc statistics, this first randomized multicenter study has determined a DLTT for Vinorelbine in 90 women with MBC. Additional studies are ongoing to further assess the relevance of this trial design method that could prove useful for improving the safety of anticancer drugs during their clinical development. Support Pierre Fabre Oncology, Ligue Bourguignonne contre le Cancer No significant financial relationships to disclose.
Collapse
Affiliation(s)
- B. Coudert
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - C. Focan
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - D. Genet
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - S. Giacchetti
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - M. Lentz
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - S. Marreaud
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - B. Baron
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - T. Gorlia
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| | - F. Lévi
- Centre François Leclerc, Dijon, France; Centre Hospitalier St. Joseph, Liege, Belgium; CHU de Limoges, Limoges, France; CHU de St Louis, Paris, France; EORTC Data Center, Brussels, Belgium; CHU Paul Brousse, Paris, France
| |
Collapse
|
27
|
Bouchahda M, Adam R, Giacchetti S, Li XM, Castaing D, Gholam D, Kunstlinger F, Jasmin C, Machover D, Lévi F. Effective salvage therapy of liver-only colorectal cancer metastases with chronomodulated irinotecan-fluorouracil-oxaliplatin via hepatic artery infusion. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3585] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3585 Background: Cell cycle and pharmacology genes are controlled by the molecular clock in normal liver but not in tumors (Filipski et al. JNCI 2005). As a result, circadian-based hepatic artery infusions of 3 main active drugs (ChronoHAI) could improve both tolerability and efficacy in patients (pts) with liver metastases from colorectal cancer. Methods: The therapeutic potential of 3-drug chronoHAI was evaluated in 28 heavily pretreated non hospitalized pts with metastatic colorectal cancer (MCC). They received 5-day (d) q21 d courses (c) with d1 irinotecan (160 mg/m2 from 2 to 8 am, peak at 5 am) and d2–5 oxaliplatin (20 mg/m2/d from 10 am to 10 pm, peak at 4 pm) and 5-fluorouracil (600 mg/m2/d from 10 pm to 10 am, peak at 4 am). 149 courses (c) were given (median, 5 ; 1–15) using a multichannel pump (Mélodie, Aguettant, F). Toxicity was assessed q21 d and response q3 c with CT scan. Results: Pt characteristics: prior chemotherapy lines 1/2/3/4+: 3/4/8/13 pts; WHO Performance Status 0/1/2/3 : 12/9/6/1 pts; median age: 63 years (32–73); liver only: 21 pts; liver and lung: 7 pts. Treatment was withdrawn for thrombosis (6 pts) and/or Grade (gr) 3 abdominal pain (3 pts). Grade 3–4 diarrhea and vomiting respectively occurred in 6 pts (21%) and 4 pts (14%) and were the main toxicities. Leucopenia, anemia and thrombocytopenia were respectively encountered in 5, 2 and 1 pt (< 18%). NCIC gr 3 sensory neuropathy occurred in 4 pts and alopecia in 3 pts. Of 25 pts with measurable lesions, disease progressed in 11 pts (exclusively outside the liver for 3 pts) and was controlled in 14 pts (56%), including 8 objective responses - 32% [95% C.L. 13.4 to 50.6]. Partial hepatectomy was performed in 3 pts with measurable disease (12%): R0 (2 PR) and R1 (1 SD). Median Progression free survival is 5 months [2.5 to 7.5] and median survival is 18.4 mo [10.5 to 26.3]. Five pts are alive at 2 to 51 mo. Conclusions: 3-drug chronoHAI is safe in heavily pretreated pts and achieves consistent activity against colorectal cancer liver metastases despite prior failure to oxaliplatin, irinotecan and fluorouracil. The addition of systemic molecular targeted therapy could be useful for preventing extra hepatic dissemination. Supported by ARTBC, Hôpital P. Brousse, Villejuif, France No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. Bouchahda
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - R. Adam
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - S. Giacchetti
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - X. M. Li
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - D. Castaing
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - D. Gholam
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - F. Kunstlinger
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - C. Jasmin
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - D. Machover
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| | - F. Lévi
- Hôpital Paul Brousse Service de Cancérologie, Villejuif, France; Hôpital Paul Brousse Centre Hépato-Biliaire, Villejuif, France; INSERM U 776, Villejuif, France; INSERM U 776 & Hôpital Paul Brousse Cancérologie, Villejuif, France
| |
Collapse
|
28
|
Sebagh M, Plasse M, Lévi F, Adam R. Severe hepatic sinusoidal obstruction and oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer: a real entity? Ann Oncol 2005; 16:331; author reply 332-3. [PMID: 15668292 DOI: 10.1093/annonc/mdi040] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
|
29
|
Abstract
The relevance of gemcitabine timing for chronotherapeutic optimisation was investigated. Healthy mice received multiple doses of gemcitabine (120, 160 or 200 mg kg−1 injection (inj)−1) at one of six circadian times (3, 7, 11, 15, 19 or 23 h after light onset – HALO) on days 1, 4, 7 and 10 or a single dose of gemcitabine (400 mg kg−1) at 11 or 23 HALO±cisplatin (5 mg kg−1 at 1 min, 4 or 8 h later). Mice bearing Glasgow osteosarcoma received multiple doses of gemcitabine (200 mg kg−1 inj−1) at 11 or 23 HALO±cisplatin (5 mg kg−1 inj−1 at 1 min or 4 h later) on days of 10, 13, 16 and 19 following tumour inoculation. A circadian rhythm in body weight loss was statistically validated, with 1030 HALO corresponding to the least toxic time (95% CL, 0800 to 1300). Gemcitabine dosing produced least body weight loss and least neutropenia after injection at 11 vs 23 HALO, whether the drug was given alone or with cisplatin (P=0.001). Gemcitabine–cisplatin tolerability was improved by dosing gemcitabine at 11 HALO and CDDP at 15 HALO (P<0.001). The administration of this schedule to tumour-bearing mice increased median survival three-fold as compared to treatments where both drugs were given simultaneously at 11 or 23 HALO (P=0.02). The optimal schedule would correspond to the delivery of gemcitabine upon awakening and cisplatin near mid-activity in cancer patients.
Collapse
Affiliation(s)
- X M Li
- INSERM E 354 Chronothérapeutique des Cancers and Université Paris XI, Hôpital Paul Brousse, 14-16 Avenue Paul Vaillant Couturier, Villejuif 94800, France.
| | | | | | | | | | | | | |
Collapse
|
30
|
Gholam D, Giacchetti S, Hauteville D, Bouchahda M, Chaibi P, Jasmin C, Lévi F. Chronomodulated fluorouracil (F), leucovorin (L), oxaliplatin (O) with or without irinotecan (I) (chrono FLO or IFLO) in elderly patients (EP) with metastatic colorectal cancer (MCC): A single institution experience. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.8218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- D. Gholam
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| | - S. Giacchetti
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| | - D. Hauteville
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| | - M. Bouchahda
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| | - P. Chaibi
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| | - C. Jasmin
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| | - F. Lévi
- Hosp Paul Brousse, Villejuif, France; Hosp Charlefoix, Ivry sur Seine, France; INSERM E0354 Hosp Paul Brousse, Villejuif, France
| |
Collapse
|
31
|
Beau J, Delaunay F, Lacoche S, Gréchez-Cassiau A, Lévi F. [Algorithm of determination of circadian gene expression profiles analysed with DNA microarrays]. Pathol Biol (Paris) 2005; 53:295-9. [PMID: 15939142 DOI: 10.1016/j.patbio.2004.12.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/03/2004] [Accepted: 12/07/2004] [Indexed: 05/02/2023]
Abstract
DNA microarrays allow to simultaneously determine the expression level of thousands of genes. A nycthemeral study must enable to conclude which ones show a circadian rhythm. Two aspects prove this to be quite difficult: firstly, what does "circadian" exactly mean and how to quantify this qualification, and secondly which genes pertain to this definition. Our method, derived from linear optimisation procedures, consists in determining a cost function, depending from magnitudes characterising the notion of circadian rhythm. Given number of genes present on the microarray are known to be expressed rhythmically; their time series are considered as reference series. We have further constructed random series having the same temporal structure as the circadian gene series. We then carried out an optimisation procedure to determine the weighting coefficients in order to obtain a cost function value which orders the time series as follows: the reference series are in the first rows and the random series have low scores. We have tested this method on over 6000 genes expressed in mouse liver. We obtained a circadian gene detection probability of 100% with a false positive rate inferior to 1%.
Collapse
Affiliation(s)
- J Beau
- Chronothérapeutique des cancers, Inserm E 0354, hôpital Paul-Brousse, 12, avenue P. Vaillant-Couturier, 94800 Villejuif, France.
| | | | | | | | | |
Collapse
|
32
|
Lévi F, Gorlia T, Tubiana N, Smaaland R, Humblet Y, Canon JL, Lentz MA, Focan C, Bjarnason G, Giacchetti S. Gender as a predictor for optimal dynamic scheduling of oxaliplatin, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer. Results from EORTC randomized phase III trial 05963. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3587] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Lévi
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - T. Gorlia
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - N. Tubiana
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - R. Smaaland
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - Y. Humblet
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - J. L. Canon
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - M. A. Lentz
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - C. Focan
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - G. Bjarnason
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| | - S. Giacchetti
- INSERM, Villejuif, France; E. O. R. T. C., Bruxelles, Belgium; C. H. U. Dupuytren, Limoges, France; Haukland Hosp, Bergen, Norway; Clin Univ St-Luc, Bruxelles, Belgium; Clin Notre-Dame, Charleroi, Belgium; Les Clin Saint-Joseph, Liège, Belgium; Toronto Sunnybrook Regional Cancer Ctr, Toronto, ON, Canada; Hôpital Paul Brousse, Villejuif, France
| |
Collapse
|
33
|
Bouchahda M, Tanaka K, Adam R, Giacchetti S, Brezault-Bonnet C, Li XM, Gholam D, Ghémard O, Jasmin C, Lévi F. Three-drug chronotherapy via hepatic artery as salvage treatment for patients with liver-only metastases from colorectal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3616] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. Bouchahda
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - K. Tanaka
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - R. Adam
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - S. Giacchetti
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - C. Brezault-Bonnet
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - X. M. Li
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - D. Gholam
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - O. Ghémard
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - C. Jasmin
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| | - F. Lévi
- Service de Cancérologie Hôpital Paul Brousse, Villejuif, France; INSERM E0354 Hôpital Paul Brousse, Villejuif, France; Ctr Hépatobiliaire Hôpital Paul Brousse, Villejuif, France
| |
Collapse
|
34
|
Abstract
At all times, cycles have focused men's attention and fashioned his life. Today, thanks to genetic, one can find tracks of circadian rhythms programming until cell's DNA, and this in a very amazing and similar manner from amoebas to mammals. A particular rhythm interests the researcher in oncology: the circadian rhythm of melatonin. It stands at the junction of several domains: somatic, immune and psychic, through the many receptors found on leukocytes, through the links between this hormone production and the one of many cytokines but also with activity, life habits and "stress". On an other hand, antioxydant action of melatonin gives a serious argument concerning its possible role in cancer aetiology. As for them, studies on sleep confirm the large ubiquity of biological cycles, for instance thanks to the observation of the impact of particular genetic mutations on advance or delayed sleep syndrome. Because of the great diversity of cyclic phenomena, the study of chronobiology cannot be undertaken today without a wide interdisciplinary collaboration. During the 13th congress of the "Association Francaise de Chronobiologie Medicale", this study has been continued mainly in three different directions of research: fundamental, applied and transverse. Many original experimental results have been presented and new ways of multidisciplinary research specified. The important scientific fecundity of this very convivial annual congress never lacks to satisfy its participants: it continues to favour the onset of new projects, enabling to avoid major shelves thanks to the constructive criticism of each domain specialists.
Collapse
|
35
|
Adam R, Sebagh M, Plasse M, Karam V, Giachetti S, Azoulay D, Bouchahda M, Jasmin C, Castaing D, Lévi F. Impact of preoperative systemic chemotherapy on liver histology and outcome of hepatic resection for colorectal cancer liver metastases (CRLM). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3529] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- R. Adam
- Paul Brousse Hosp, Villejuif, France
| | - M. Sebagh
- Paul Brousse Hosp, Villejuif, France
| | - M. Plasse
- Paul Brousse Hosp, Villejuif, France
| | - V. Karam
- Paul Brousse Hosp, Villejuif, France
| | | | | | | | - C. Jasmin
- Paul Brousse Hosp, Villejuif, France
| | | | - F. Lévi
- Paul Brousse Hosp, Villejuif, France
| |
Collapse
|
36
|
Li XM, Beau J, Delagrange P, Mocaër E, Lévi F. Circadian rhythm entrainment with melatonin, melatonin receptor antagonist S22153 or their combination in mice exposed to constant light. J Pineal Res 2004; 37:176-84. [PMID: 15357662 DOI: 10.1111/j.1600-079x.2004.00152.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
The ability of daily melatonin and the melatonin receptor antagonist, S22153, to entrain circadian system function was investigated in mice with atypical melatonin rhythm. B6D2F(1) mice were first synchronized to a LD 12:12 for approximately 2 wk, then exposed to continuous light (LL) until study completion. After 10-18 days of LL exposure, mice received daily subcutaneous (s.c.) melatonin at a dose of 0.1, 1 or 10 mg/kg/day (exp. 1) or daily intraperitoneal (i.p.) S22153 (20 mg/kg/day) with or without melatonin (1 mg/kg/day, exp. 2) at subjective zeitgeber time (ZT) 10 for 19 days. Then all the mice were exposed to LL for another 10 days. Spectral analysis showed that initial LL lengthened the period of both rhythms by approximately 1.5 hr as compared with LD 12:12. No entrainment of either rhythm was found in controls. Conversely, daily melatonin-only, S22153-only or their combination set the temperature and activity periods to approximately 24 hr and produced a significant increase of the circadian amplitude of both rhythms as compared with controls. However, after treatment withdrawal, the dominant period lengthened to approximately 25.5 hr in mice receiving either melatonin or S22153. On the contrary, the period remained close to 24 hr for the 10 days following withdrawal of combined S22153 and melatonin. Such sustained pharmacological resetting of circadian function could display therapeutic potential against external resynchronization resulting from defective photoperiodic entrainment.
Collapse
Affiliation(s)
- X M Li
- INSERM E 0354 'Chronothérapeutique des Cancers', Université Paris XI, Hôpital Paul Brousse, 94807 Villejuif Cedex, France.
| | | | | | | | | |
Collapse
|
37
|
Giacchetti S, Bjarnason G, Garufi C, Tubiana-Mathieu N, Iacobelli S, Dogliotti L, Smaaland R, Focan C, Coudert B, Lévi F. First line infusion of 5-fluorouracil, leucovorin and oxaliplatin for metastatic colorectal cancer : 4-day chronomodulated (FFL4–10) versus 2-day FOLFOX2. A multicenter randomized Phase III trial of the Chronotherapy Group of the European Organization for Research and Treatment of Cancer (EORTC 05963). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3526] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- S. Giacchetti
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - G. Bjarnason
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - C. Garufi
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - N. Tubiana-Mathieu
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - S. Iacobelli
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - L. Dogliotti
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - R. Smaaland
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - C. Focan
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - B. Coudert
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| | - F. Lévi
- Hopital Paul Brousse and INSERM, Villejuif, France; Toronto-Sunnybrook Regional Cancer Centre, Toronto, ON, Canada; Istituto Regina Elena, Roma, Italy; Centre Hospitalier Universitaire Dupuytren, Limoges, France; Universita G d'Annunzio di Chieti, Chieti, Italy; Ospedale San Luigi, Orbassano, Italy; Haukland Hospital, Bergen, Norway; Les Cliniques Saint-Joseph, Liège, Belgium; Centre Georges-François Leclerc, Dijon, France; Hopital Paul Brousse & INSERM, Villejuif, France
| |
Collapse
|
38
|
Innominato PF, Rich T, Boerner J, Mormont MC, Iacobelli S, Jasmin C, Lévi F. High serum TGFα, TNFα and IL6 correlate with abnormal circadian rhythms in patients with metastatic colorectal cancer (MCC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.9650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. F. Innominato
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| | - T. Rich
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| | - J. Boerner
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| | - M. C. Mormont
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| | - S. Iacobelli
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| | - C. Jasmin
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| | - F. Lévi
- INSERM E0354 Unité de Chronothérapie, Hôpital Paul Brousse, Villejuif, France; University of Virginia, Department of Radiation Oncology, Charlottesville, VA; Università di Chieti, Cattedra di Oncologia Medica, Chieti, Italy; Hôpital Paul Brousse, Service de Cancérologie, Villejuif, France
| |
Collapse
|
39
|
Abstract
Meal timing can reset circadian clocks in peripheral tissues. We investigated the effects of such non-photic entrainment on tumor growth rate. Two experiments involved a total of 61 male B6D2F(1) mice synchronized with an alternation of 12 h of light (L) and 12 h of darkness (D) (LD12:12). Mice were randomly allocated to have access to food ad libitum, or restricted to 4 or 6 h during L or D. Rest-activity and body temperature, two circadian outputs, were monitored with an intra-peritoneal sensor. Glasgow osteosarcoma was inoculated into both flanks of each mouse ten days after meal timing onset. Before tumor inoculation, meal timing during D amplified the 24-h rhythms in rest-activity and body temperature with minimal phase alteration as compared to ad libitum feeding. Conversely, meal timing during L induced dominant 12-h or 8-h rhythmic components in activity, nearly doubled the 24-h amplitude of body temperature and shifted its acrophase (time of maximum) from approximately mid-D to approximately mid-L. Thirteen days after tumor inoculation, mean tumor weight (+/- SEM, mg) was 1503 +/- 150 in ad libitum mice, 1077 +/- 157 in mice fed during D and 577 +/- 139 in mice fed during L (ANOVA, p < 0.0001). Overall survival was prolonged in the mice fed during L (median, 17.5 days, d) as compared with those fed during D (14.5 d) or ad libitum (14 d) (Log Rank, p = 0.0035). The internal desynchronization produced by meal timing during L slowed down tumor progression, an effect possibly resulting from improved host-mediated tumor control and/or altered tumor circadian clocks.
Collapse
Affiliation(s)
- M W Wu
- INSERM E 0354 Chronothérapeutique des cancers, Hôpital Paul Brousse and Université Paris XI, 94807 Villejuif Cedex, France
| | | | | | | |
Collapse
|
40
|
Tanaka K, Adam R, Shimada H, Azoulay D, Lévi F, Bismuth H. Role of neoadjuvant chemotherapy in the treatment of multiple colorectal metastases to the liver. Br J Surg 2003; 90:963-9. [PMID: 12905549 DOI: 10.1002/bjs.4160] [Citation(s) in RCA: 176] [Impact Index Per Article: 8.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
BACKGROUND The role of neoadjuvant chemotherapy for patients with multiple (five or more) bilobar hepatic metastases irrespective of initial resectability is still under scrutiny. The purpose of this study was to compare the outcome of hepatectomy alone with that of hepatectomy after neoadjuvant chemotherapy for multiple bilobar hepatic metastases from colorectal cancer. METHODS Retrospective data were collected from 71 patients after hepatectomy for five or more bilobar liver tumours. The outcome of 48 patients treated by neoadjuvant chemotherapy followed by hepatectomy was compared with that of 23 patients treated by hepatectomy alone. RESULTS Patients who received neoadjuvant chemotherapy had better 3- and 5-year survival rates from the time of diagnosis than those who did not (67.0 and 38.9 versus 51.8 and 20.7 per cent respectively; P = 0.039), and required fewer extended hepatectomies (four segments or more) (39 of 48 versus 23 of 23; P = 0.027). Multivariate analysis showed neoadjuvant chemotherapy to be an independent predictor of survival. CONCLUSION In patients with bilateral multiple colorectal liver metastases, neoadjuvant chemotherapy before hepatectomy was associated with improved survival and enabled complete resection with fewer extended hepatectomies.
Collapse
Affiliation(s)
- K Tanaka
- Department of Surgery II, Yokohama City University School of Medicine, Yokohama, Japan.
| | | | | | | | | | | |
Collapse
|
41
|
Abstract
The EORTC Chronotherapy Group (CTG) stemmed from the International Organisation for Cancer Chronotherapy(IOCC) in 1996. The IOCC was the first to initiate large scale multicentre international chronotherapy trials, for the purpose of investigating the relevance of chronomodulated or timed administration of cancer therapy based on biological rhythms. Programmable pumps for cytotoxic chronodelivery and actigraph devices to monitor circadian rhythm alterations linked to cancer were also developed. The unique expertise of the IOCC with regard to cancer chronotherapy furthered its development within the EORTC. EORTC offers broad expertise in clinical cancer research and opportunities for scientific recognition, inter-group collaborations and translational research. Over the past 5 years, EORTC CTG has grown from 16 to 48 centres in 12 different countries. It is currently conducting seven multicentre chronotherapy trials, which test the relevance of adapting cancer treatment delivery to circadian rhythms. The group aims at developing multiple collaborations to establish a chronotherapy network involving institutions with expertise ranging from experimental chronobiology to new drug testing, disease-specific management and quality of life or survival issues.
Collapse
Affiliation(s)
- B Coudert
- Centre Georges François Leclerc, 1, rue du Professeur-Marion, BP 77980, 21079 cedex, Dijon, France.
| | | | | | | | | |
Collapse
|
42
|
Porsin B, Formento JL, Filipski E, Etienne MC, Francoual M, Renée N, Magné N, Lévi F, Milano G. Dihydropyrimidine dehydrogenase circadian rhythm in mouse liver: comparison between enzyme activity and gene expression. Eur J Cancer 2003; 39:822-8. [PMID: 12651209 DOI: 10.1016/s0959-8049(02)00598-1] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme of 5-fluorouracil (FU) catabolism. The relevance of the measurement of DPD activity for identifying DPD-deficient patients is lessened by circadian variability in DPD activity. Our purpose was to determine whether or not DPD mRNA is sustained by a circadian rhythm. Synchronised mice (male B6D2F1) were sacrificed at 3, 7, 11, 15, 19 or 23 Hours After Light Onset (HALO; eight mice per time-point). Liver DPD activity was determined by a radio-enzymatic assay and liver DPD expression by a reverse transcriptase-polymerase chain reaction (RT-PCR) enzyme-linked immunosorbent assay (ELISA) method. Mice synchronisation was controlled by leucocyte and neutrophil counts. Individual DPD activity ranged from 555 to 1575 pmol/min/mg prot; mean DPD activity was highest at 3 HALO (mean+/-standard error of the mean (S.E.M.); 1105+/-70) and lowest at 15 HALO (889+/-71). Individual liver DPD expression varied from 761 to 3481 units (DPD/beta actin ratio); the mean was lowest at 3 HALO (1406+/-112) and highest at 15 HALO (2067+/-214). Cosinor analysis indicated that respective double amplitudes of DPD activity and expression were 21 and 30% of the 24-h mean. The acrophases for activity and expression were 6:40 and 14:10 HALO, respectively, meaning that maximum activity occurred 16 h after the maximum observed expression. These results, revealing the existence of a circadian rhythm in DPD expression, should stimulate further studies to enhance our understanding of the molecular mechanisms involved in the circadian regulation of the DPD enzyme.
Collapse
Affiliation(s)
- B Porsin
- Oncopharmacology Unit, Centre Antoine Lacassagne, Nice, France
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Granda TG, D'Attino RM, Filipski E, Vrignaud P, Garufi C, Terzoli E, Bissery MC, Lévi F. Circadian optimisation of irinotecan and oxaliplatin efficacy in mice with Glasgow osteosarcoma. Br J Cancer 2002; 86:999-1005. [PMID: 11953836 PMCID: PMC2364142 DOI: 10.1038/sj.bjc.6600168] [Citation(s) in RCA: 44] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2001] [Revised: 12/17/2001] [Accepted: 01/07/2002] [Indexed: 12/27/2022] Open
Abstract
The relevance of circadian rhythms in irinotecan and oxaliplatin tolerability was investigated with regard to antitumour activity. Mice bearing Glasgow osteosarcoma (GOS) received single agent irinotecan (50 or 60 mg kg(-1) per day) or oxaliplatin (4 or 5.25 mg kg(-1) per day) at one of six dosing times expressed in hours after light onset (3, 7, 11, 15, 19 or 23 hours after light onset). Irinotecan (50 mg kg(-1) per day) and oxaliplatin (4 or 5.25 mg kg(-1) per day) were given 1 min apart at 7 or 15 hours after light onset, or at their respective times of best tolerability (7 hours after light onset for irinotecan and 15 hours after light onset for oxaliplatin) or worst tolerability (15 hours after light onset for irinotecan and 7 hours after light onset for oxaliplatin). Tumour growth rate was nearly halved and per cent increase in estimated life span (% ILS) was - doubled in the mice receiving irinotecan at 7 hours after light onset as compared to 15 hours after light onset (P<0.05). Results of similar magnitude were obtained with oxaliplatin for both endpoints, yet with 7 hours after light onset corresponding to least efficacy and 15 hours after light onset to best efficacy (P<0.05). Irinotecan addition to oxaliplatin proved therapeutic benefit only if the schedule consisted of irinotecan administration at 7 hours after light onset and oxaliplatin delivery at 15 hours after light onset, i.e. when both drugs were given near their respective "best" circadian times. These would correspond to the middle of the night for irinotecan and the middle of the day for oxaliplatin in humans.
Collapse
Affiliation(s)
- T G Granda
- INSERM E-0118 Chronothérapeutique des cancers and Université Paris XI, Institut du Cancer et d'Immunogénétique, Hôpital Paul Brousse, 14, av. Paul Vaillant Couturier, 94800 Villejuif, France
| | | | | | | | | | | | | | | |
Collapse
|
44
|
Abstract
The EORTC Chronotherapy Group (CTG) stemmed from the International Organisation for Cancer Chronotherapy (IOCC) in 1996. The IOCC was first to initiate large scale multicentre international chronotherapy trials, for the purpose of investigating the relevance of chronomodulated or timed administration of cancer therapy based on biological rhythms. Programmable pumps for cytotoxic chronodelivery and actigraph devices to monitor circadian rhythm alterations linked to cancer were also developed. The unique expertise of the IOCC with regard to cancer chronotherapy furthered its development within the EORTC. The EORTC offers broad expertise in clinical cancer research and opportunities for scientific recognition, intergroup collaborations and translational research. Over the past 5 years, the EORTC CTG has grown from 16 to 48 centres in 12 different countries. It is currently conducting seven multicentre chronotherapy trials which test the relevance of adapting cancer treatment delivery to circadian rhythms. The group aims at developing multiple collaborations to establish a chronotherapy network involving institutions with expertise ranging from experimental chronobiology to new drug testing, disease-specific management and quality of life or survival issues.
Collapse
Affiliation(s)
- B Coudert
- Centre Georges François Leclerc, 1 rue du Professeur Marion, BP 77980, 21079, Dijon cedex, France.
| | | | | | | |
Collapse
|
45
|
Curé H, Chevalier V, Adenis A, Tubiana-Mathieu N, Niezgodzki G, Kwiatkowski F, Pezet D, Perpoint B, Coudert B, Focan C, Lévi F, Chipponi J, Chollet P. Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:1175-81. [PMID: 11870158 DOI: 10.1200/jco.2002.20.5.1175] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE To study tolerability and efficacy of an intensified chronomodulated schedule of fluorouracil (5-FU) and l-folinic acid (l-FA) as first-line treatment of metastatic colorectal cancer, 5-FU was given near individually determined dose-limiting toxicity in a multicenter phase II trial. PATIENTS AND METHODS One hundred patients (68 men and 32 women, median age 62 years, World Health Organization performance status less-than-or-equal 2) with previously untreated and inoperable metastases received chronomodulated daily infusion of 5-FU/l-FA (from 10:00 PM to 10:00 AM with peak at 4:00 AM). 5-FU dose was escalated from 900 to 1,100 mg/m(2)/d with fixed dose of l-FA at 150 mg/m(2)/d for 4 days every 14 days. RESULTS 5-FU dose escalation was achieved in 66% of the patients. Grade 3 to 4 toxicities mainly consisted of nausea or vomiting (14% of patients and 1.5% of courses), hand-foot syndrome (38% of patients and 8% of courses), mucositis (26% of patients and 4% of courses), and diarrhea (21% of patients and 2.3% of courses). Objective response rate (ORR) was 41% (95% confidence interval, 31.5% to 50.5%). Twenty patients underwent metastases surgery; among these, 12 had a complete resection. Median progression-free survival was 7 months. Median survival was 17 months; 28% of the patients were alive at 2 years and 18.6% at 3 years. CONCLUSION The ORR achieved with intensified chronomodulated delivery of 5-FU/l-FA was nearly twice as high as that earlier obtained by our cooperative group using less intensive 5-FU/FA chronotherapy.
Collapse
Affiliation(s)
- H Curé
- Centre Jean Perrin and L'Institut National de la Santé et de la Recherche Médicale U484, Clermont-Ferrand, France
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Bensmaïne MA, Marty M, de Gramont A, Brienza S, Lévi F, Ducreux M, François E, Gamelin E, Bleiberg H, Cvitkovic E. Factors predicting efficacy of oxaliplatin in combination with 5-fluorouracil (5-FU) +/- folinic acid in a compassionate-use cohort of 481 5-FU-resistant advanced colorectal cancer patients. Br J Cancer 2001; 85:509-17. [PMID: 11506488 PMCID: PMC2364084 DOI: 10.1054/bjoc.2001.1953] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023] Open
Abstract
A statistical analysis was performed on the patient data collected from two compassionate-use programmes using oxaliplatin (Eloxatin(R)) + 5-fluorouracil (5-FU) +/- folinic acid (FA), to identify predictive factors for oxaliplatin-based salvage treatment in patients with 5-FU-resistant advanced colorectal cancer (ACRC). 481 5-FU-resistant ACRC patients, most with performance status < or = 2, > or = 3 involved sites, and > or = 2 prior lines of chemotherapy, received oxaliplatin + 5-FU +/- FA. Prognostic factors associated with overall response rate (ORR), time to progression (TTP) and overall survival (OS) were identified using univariate and multivariate logistic and/or Cox proportional hazards analyses. The ORR was 16% (95% CI: 13-20), the median TTP was 4.2 months (95% CI: 3.4-4.6), and the median OS was 9.6 months (95% CI: 8.6-10.6). The multivariate analysis indicated poor (> or = 2 WHO) performance status (PS), a large number of prior chemotherapy regimens (> or = 3), a low baseline haemoglobin level (< 10 g/dl), and a triweekly (vs biweekly) treatment administration schedule as significantly associated (P< 0.05) with a lower ORR. Sex (male), number of organs involved (> or =3) and alkaline phosphatase (AP) level (> or = 2 x the upper limit of normal) were associated (P< 0.05) with shorter TTP. Poor PS, a large number of organs involved, and elevated AP were independently and significantly correlated with shorter OS. Our analysis identified a relationship between efficacy results of oxaliplatin + 5-FU +/- FA treatment in 5-FU-resistant ACRC patients and baseline prognostic factors related to PS, extent of disease and number of prior regimens.
Collapse
Affiliation(s)
- M A Bensmaïne
- Cvitkovic et Associés Consultants, 18-20 rue Pasteur, 94278 Kremlin-Bicêtre, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
Cell physiology is regulated by a 24-hour clock, consisting of interconnected molecular loops, involving at least nine genes. The cellular clock is coordinated by the suprachiasmatic nucleus, a hypothalamic pacemaker which also helps the organism to adjust to environmental cycles. This circadian organisation brings about predictable changes in the body's tolerance and tumour responsiveness to anticancer agents, and possibly also for cancer promotion or growth. The clinical relevance of the chronotherapy principle, ie treatment regimens based upon circadian rhythms, has been demonstrated in randomised, multicentre trials. Chronotherapeutic schedules have been used to document the safety and activity of oxaliplatin against metastatic colorectal cancer and have formed the basis for a new approach to the medicosurgical management of this disease, which achieved unprecedented long-term survival. The chronotherapy concept offers further promise for improving current cancer-treatment options, as well as for optimising the development of new anticancer or supportive agents.
Collapse
Affiliation(s)
- F Lévi
- Chronotherapy Unit in the Medical Oncology service at Paul Brousse Hospital, Villejuif, France.
| |
Collapse
|
48
|
Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, Lévi F. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res 2001; 61:1996-2001. [PMID: 11280758] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The therapeutic index of docetaxel, doxorubicin and their combination may be improved by an adequate selection of the circadian time of administration. The present study constitutes a prerequisite to testing the clinical relevance of chronotherapy in human breast cancer. Three experiments were performed in C3H/HeN mice. Each treatment modality was administered i.v. once a week for 3 weeks at one of six circadian stages, during the light span, when the mice were resting: 3, 7, and 11 h after light onset (HALO), or during darkness, when the mice were active: 15, 19, and 23 HALO. The circadian time dependency of single agent tolerability was investigated in healthy mice using four dose levels for docetaxel (38.8, 23.3, 14, and 8.4 mg/kg/injection) and for doxorubicin (13.8, 8.3, 5 and 3 mg/kg/injection; experiment 1). The circadian time dependency of each single agent efficacy was studied in MA13/C-bearing mice, using two dose levels of docetaxel (38.8 or 23.3 mg/kg/injection) or doxorubicin (8.3 or 5 mg/kg/injection; experiment 2). The toxicity and the efficacy of the simultaneous docetaxel-doxorubicin combination were assessed as a function of dosing time in experiment 3. Two combinations were tested (A, 16.3 mg/kg/injection of docetaxel and 2.5 mg/kg/injection of doxorubicin; and B, 11.6 and 3.5 mg/kg/injection, respectively) at each of the above six circadian times. Mortality, body weight change, and tumor size were recorded for 60-70 days in each experiment. Single agent docetaxel or doxorubicin was significantly best tolerated near the middle of the rest span (7 HALO) and most toxic in the middle of the activity phase (19 HALO). Docetaxel or doxorubicin as a single drug were also most effective at 7 HALO, irrespective of dose. Treatment at 7 HALO produced highest rates of complete tumor inhibition (81% versus 11% at 3 HALO for docetaxel, p from chi2 <0.001, and 69% versus 44% at 11 HALO for doxorubicin, not significant) and highest day 60 survival rate (100% versus 28% at 3 HALO for docetaxel, p from chi2 <0.001 and 89% versus 69% at 15 HALO for doxorubicin, not significant). Docetaxel-doxorubicin combinations were most effective following dosing in the beginning of the rest span or short after the onset of the activity span, with regard to the rates of both complete tumor inhibitions (45% at 3 HALO versus 15% at 19 HALO) and day 70 survival rates (85% and 80% at 3 and 7 HALO respectively, versus 20% at 19 HALO). The efficacy of single agent docetaxel or doxorubicin and that of their combination varied largely as a function of circadian dosing time. Single agent docetaxel at 7 HALO was the best treatment option in this model with regard to both tolerability and efficacy. This timing may correspond to the middle of the night in cancer patients.
Collapse
Affiliation(s)
- T G Granda
- Laboratoire Rythmes Biologiques et Chronothérapeutique (Université Paris XI, Institut du Cancer et d'Immunogenetique), H pital Paul Brousse, Villejuif, France
| | | | | | | | | | | | | |
Collapse
|
49
|
Lévi F, Giacchetti S, Zidani R, Brezault-Bonnet C, Tigaud JM, Goldwasser F, Misset JL. Chronotherapy of colorectal cancer metastases. Hepatogastroenterology 2001; 48:320-2. [PMID: 11379299] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Chronotherapy has consisted in the adaptation of chemotherapeutic drug delivery to circadian (approximately 24-hour) rhythms. This can be achieved in fully ambulatory patients using multichannel programmable pumps. Up to approximately 1500 patients with metastatic colorectal cancer have been registered in one of 15 trials testing the relevance of this treatment method with 5-fluorouracil +/- leucovorin +/- oxaliplatin. Chronotherapy was shown as significantly less toxic and more effective than constant rate infusion in 2 consecutive multicenter trials. High efficacy and good tolerability permitted secondary surgical resection of previously inoperable metastases, with apparent survival improvement (3-year survival > or = 20%) and cures in some patients. This strategy is currently undergoing further testing within the European Organization for Research and Treatment of Cancer. Nevertheless, combining chronotherapy with surgery of colorectal cancer metastases can be readily offered to patients as a safer therapeutic option for optimizing outcome.
Collapse
Affiliation(s)
- F Lévi
- Centre de Chronothérapie, Fédération des Maladies Sanguines, Immunitaires et Tumorales Hôpital Paul Brousse, Villejuif, France.
| | | | | | | | | | | | | |
Collapse
|
50
|
Marchenay C, Cellarier E, Lévi F, Rolhion C, Kwiatkowski F, Claustrat B, Madelmont JC, Chollet P. Circadian variation in O6-alkylguanine-DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. Int J Cancer 2001; 91:60-6. [PMID: 11149421 DOI: 10.1002/1097-0215(20010101)91:1<60::aid-ijc1010>3.0.co;2-n] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Cytotoxic agents such as chloroethylnitrosoureas (CENUs) mostly alkylate DNA on the O6-guanine position. This highly mutagenic lesion can be repaired by O6-alkylguanine-DNA alkyltransferase (AGT), which removes the alkyl group by accepting it to the cysteine residue of its active site. AGT activity displayed a circadian rhythm in mouse liver, coincident with that of CENU tolerability. We investigated whether AGT activity displayed a circadian rhythm in human circulating mononuclear cells (MNCs). The study was performed in 12 healthy volunteers aged 19 to 31 years. Circadian synchronization was verified with rest/activity cycle as assessed with wrist actigraphy and plasma cortisol and melatonin rhythms. Subjects were hospitalized for 24 hr and blood samples were obtained at 08:00, 12:00, 16:00, 20:00, 22:00, 00:00, 02:00, 04:00 and 08:00 overnight. MNCs were isolated on Ficoll immediately after blood sampling and frozen at -196 degrees C until AGT activity determination by HPLC. Mean AGT activity (+/- SEM) varied from 821 +/- 67 fmol/mg of total proteins at noon (trough), up to 1,055 +/- 80 fmol/mg at midnight (peak), i.e., by approximately 30%. A circadian rhythm was statistically validated with both analysis of variance (p < 0.009) and cosinor (p < 0.02) for AGT activity in MNCs (acrophase +/- SD at 00:30 +/- 210 min) as well as for MNC circulating count and for plasma cortisol and melatonin concentrations. Despite individual variations in the extent of AGT activity rhythm (more or less pronounced according to subject), AGT activity displayed a circadian rhythm in human MNCs of our healthy study group subjects. The results warrant to further investigate AGT rhythmicity both in circulating MNCs and in target tissues of cancer patients, as a prerequisite for clinical testing of chronotherapy with alkylating agents.
Collapse
|